Every material Form 8-K Phibro Animal Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Phibro Animal Health reported higher first-quarter results for the period ended September 30, 2026, with net sales up 6% and net income up 11% from a year earlier. The company kept its fiscal 2027 guidance unchanged, and stockholders re-elected three Class I directors and ratified PricewaterhouseCoopers as auditor at the November 3, 2026 annual meeting.
Net sales of $386.8 million rose $22.9 million, or 6%, led by Mineral Nutrition, which rose 17%.
Net income of $29.5 million rose 11%, and diluted EPS of $0.72 rose $0.07 from $0.65.
Fiscal 2027 guidance was maintained: net sales of $1.55 billion to $1.60 billion and adjusted EBITDA of $258 million to $268 million.
At the November 3, 2026 annual meeting, all three director nominees were elected and PwC was ratified for the fiscal year ending June 30, 2027.
Phibro Animal Health's board declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. Holders of record at the close of business on November 25, 2026 will receive the payment on December 16, 2026.
Quarterly cash dividend of $0.12 per share on Class A and Class B common stock
Phibro Animal Health reported results for the fiscal year ended June 30, 2026, with net sales up 17% to $1.52 billion and net income up to $99.7 million from $48.3 million. It also gave fiscal 2027 guidance for net sales of $1.55 billion to $1.60 billion and adjusted diluted EPS of $3.41 to $3.59, and said it will close its Chicago Heights, Illinois plant, affecting about 100 employees.
Fiscal 2026 diluted EPS was $2.43, up $1.24, and adjusted EBITDA was $255.0 million, up 39%.
Fourth-quarter net sales were $396.7 million, up 5%, and net income was $21.7 million, up 26%.
Fiscal 2027 guidance: net income of $122 million to $132 million and adjusted EBITDA of $258 million to $268 million.
Chicago Heights production is expected to cease during the summer of 2027, with products moved to other Phibro facilities and third-party contract manufacturers.
Phibro Animal Health said Daniel (Dani) Bendheim will become Chief Executive Officer and President effective July 1, 2026, under a new employment agreement with a $850,000 base salary. He also received a grant of 300,000 performance-based restricted stock units that vest only if the company's 90-day average stock price reaches $70 to $100 by June 30, 2031.
Bendheim's base salary is $850,000 annually, with a target bonus of 50% of base salary.
The 300,000 RSUs vest in 25% increments tied to a 90-day average stock price from $70 to $100 or above, with no vesting below $70.
Severance includes six months of base salary on death or disability and up to 18 months of company-subsidized COBRA coverage on termination without Cause or resignation.
Phibro Animal Health reported results for the quarter ended March 31, 2026, with net sales of $383.5 million, up 10%, and net income of $24.0 million, up 15%. The company raised the lower end of several fiscal 2026 guidance ranges, resulting in higher midpoints, and guides to net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million. For shareholders, the filing shows higher sales and profit and a higher outlook for the fiscal year ending June 30, 2026, though Performance Products sales fell 17%.
Quarterly net sales of $383.5 million, up $35.7 million or 10%; Animal Health sales rose 13% to $291.2 million
Net income of $24.0 million, up 15%; diluted EPS of $0.59 versus $0.51 a year earlier
Fiscal 2026 guidance: net sales of $1.46 billion to $1.50 billion, adjusted EBITDA of $247 million to $255 million, and diluted EPS of $2.25 to $2.44
Revolving credit facility increased by $125 million to $435 million on April 28, 2026
Phibro Animal Health entered into Amendment No. 1 to its credit agreement with Coöperatieve Rabobank U.A., New York Branch, on April 28, 2026. The amendment increases the revolving credit commitment by $125 million, from $310 million to $435 million, giving the company more borrowing capacity under its existing facility.
Revolving credit commitment rose by $125 million, from $310 million to $435 million
Amendment No. 1 is dated April 28, 2026, and amends the Original Credit Agreement dated July 3, 2024
Rabobank acts as administrative agent, collateral agent and L/C issuer
Phibro Animal Health director Joyce J. Lee informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026. The filing states her resignation was not due to any disagreement with the company on its operations, policies or practices.
Joyce J. Lee, a Class II Director, intends to resign effective April 15, 2026
Notice was given to the company on April 13, 2026
Filing states no disagreement with the company on operations, policies or practices
Phibro Animal Health reported fiscal second-quarter results for the period ended December 31, 2025, with net sales up 21% to $373.9 million and net income rising to $27.5 million from $3.2 million a year earlier. The company also raised its fiscal 2026 guidance, now calling for net sales of $1.45 billion to $1.50 billion and adjusted EBITDA of $245 million to $255 million, which signals higher expected sales and profit for shareholders.
Net sales of $373.9 million, up 21%; net income of $27.5 million versus $3.2 million a year earlier
Diluted EPS of $0.67 versus $0.08; adjusted diluted EPS of $0.87 versus $0.55
Fiscal 2026 guidance raised: net sales of $1.45 billion to $1.50 billion; adjusted EBITDA of $245 million to $255 million
Total debt of $737.0 million and a 3.1x gross leverage ratio as of December 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Phibro Animal Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →